<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270088" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40017512</article-id><article-id pub-id-type="pmc">PMC11864922</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70088</article-id><article-id pub-id-type="publisher-id">DEO270088</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Endoscopic features of gastric neuroendocrine tumors</article-title><alt-title alt-title-type="left-running-head">MATSUEDA et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="deo270088-cr-0001" contrib-type="author"><name><surname>Matsueda</surname><given-names>Katsunori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6497-730X</contrib-id><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270088-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270088-cr-0002" contrib-type="author" corresp="yes"><name><surname>Uedo</surname><given-names>Noriya</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>noriya.uedo@gmail.com</email></address></contrib><contrib id="deo270088-cr-0003" contrib-type="author"><name><surname>Kitamura</surname><given-names>Masanori</given-names></name><xref rid="deo270088-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270088-cr-0004" contrib-type="author"><name><surname>Kanesaka</surname><given-names>Takashi</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0005" contrib-type="author"><name><surname>Morita</surname><given-names>Muneshin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-3280-6902</contrib-id><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0006" contrib-type="author"><name><surname>Shichijo</surname><given-names>Satoki</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0007" contrib-type="author"><name><surname>Maekawa</surname><given-names>Akira</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0008" contrib-type="author"><name><surname>Takeuchi</surname><given-names>Yoji</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo270088-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo270088-cr-0009" contrib-type="author"><name><surname>Higashino</surname><given-names>Koji</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0010" contrib-type="author"><name><surname>Michida</surname><given-names>Tomoki</given-names></name><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0011" contrib-type="author"><name><surname>Ishihara</surname><given-names>Ryu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8796-718X</contrib-id><xref rid="deo270088-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270088-cr-0012" contrib-type="author"><name><surname>Kawano</surname><given-names>Seiji</given-names></name><xref rid="deo270088-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270088-cr-0013" contrib-type="author"><name><surname>Otsuka</surname><given-names>Motoyuki</given-names></name><xref rid="deo270088-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="deo270088-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastrointestinal Oncology</named-content>
<institution>Osaka International Cancer Institute</institution>
<named-content content-type="country-part">Osaka</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270088-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Okayama University Hospital</institution>
<named-content content-type="country-part">Okayama</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270088-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Diagnostic Pathology and Cytology</named-content>
<institution>Osaka International Cancer Institute</institution>
<named-content content-type="country-part">Osaka</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo270088-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology and Hepatology</named-content>
<institution>Gunma University Graduate School of Medicine</institution>
<named-content content-type="country-part">Gunma</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Noriya Uedo, Department of Gastrointestinal Oncology, Osaka International Cancer Institute<break/> 3&#x02010;1&#x02010;69 Otemae, Chuo&#x02010;ku, Osaka 541&#x02010;8567, Japan<break/>Email: <email>noriya.uedo@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="22">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70088</elocation-id><history>
<date date-type="rev-recd"><day>10</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>25</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70088.pdf"/><abstract><title>Abstract</title><sec id="deo270088-sec-0010"><title>Objectives</title><p>The endoscopic features of gastric neuroendocrine tumors (G&#x02010;NETs) remain unclarified. The present study investigated the endoscopic features of G&#x02010;NETs in relation to the clinicopathological findings.</p></sec><sec id="deo270088-sec-0020"><title>Methods</title><p>This retrospective study analyzed consecutive patients with G&#x02010;NETs who received endoscopic or surgical treatment between January 2005 and December 2023. The endoscopic and clinicopathological findings of the lesions were analyzed to provide diagnostic information.</p></sec><sec id="deo270088-sec-0030"><title>Results</title><p>Among 29 patients, the characteristic endoscopic findings of G&#x02010;NETs on white&#x02010;light images were reddish color (66%), dilated vessels (83%), submucosal tumor&#x02010;like marginal elevation (59%), and central depression (48%). The gross appearance of G&#x02010;NETs was classified into two macroscopic subtypes: reddish polypoid lesions (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;17) and submucosal tumor&#x02010;like lesions (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;9). Magnifying narrow&#x02010;band imaging endoscopy revealed an absent microsurface pattern plus an irregular microvascular pattern in all cases of reddish polypoid lesions with central depressions (100%, 9/9). The findings of a reddish polypoid lesion and an absent microsurface pattern plus an irregular microvascular pattern corresponded to the subepithelial NET component close to the non&#x02010;neoplastic surface epithelium. Additionally, reddish polypoid lesions were significantly more frequent in type 1 G&#x02010;NETs than in type 3 G&#x02010;NETs (80%&#x000a0;vs. 11%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001), while submucosal tumor&#x02010;like lesions were significantly more frequent in type 3 G&#x02010;NETs than in type 1 G&#x02010;NETs (78%&#x000a0;vs. 10%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001).</p></sec><sec id="deo270088-sec-0040"><title>Conclusions</title><p>These endoscopic features should increase the index of suspicion and help clinicians to correctly diagnose G&#x02010;NETs through the pathological examination of biopsy specimens.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270088-kwd-0001">endoscopic feature</kwd><kwd id="deo270088-kwd-0002">magnifying narrow&#x02010;band imaging</kwd><kwd id="deo270088-kwd-0003">neuroendocrine tumor</kwd><kwd id="deo270088-kwd-0004">stomach</kwd><kwd id="deo270088-kwd-0005">white&#x02010;light imaging</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="10"/><word-count count="5347"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:07.04.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270088-sec-0050"><title>INTRODUCTION</title><p>The 2019 World Health Organization (WHO) classification defined epithelial neoplasms with predominant neuroendocrine differentiation as neuroendocrine neoplasms (NENs)<xref rid="deo270088-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>. NENs are classified into well&#x02010;differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on the degree of histological differentiation. NETs are further classified as grade 1&#x02013;3 (NET&#x02010;G1, NET&#x02010;G2, and NET&#x02010;G3) based on their mitotic count and cell proliferation index.</p><p>Rindi et&#x000a0;al.<xref rid="deo270088-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270088-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> divided gastric NETs (G&#x02010;NETs) into three distinct subtypes with different clinical backgrounds: type 1 G&#x02010;NETs (approximate prevalence 75%&#x02013;80%) associated with chronic atrophic gastritis (i.e., autoimmune gastritis); type 2 G&#x02010;NETs (prevalence 5%) associated with multiple endocrine neoplasia Zollinger&#x02010;Ellison syndrome; and type 3 G&#x02010;NETs (prevalence 15%&#x02013;25%) that are sporadic lesions without specific background diseases. Types 1 and 2 G&#x02010;NETs are associated with hypergastrinemia and hyperplasia of enterochromaffin&#x02010;like (ECL) cells, while type 3 G&#x02010;NETs grow without hypergastrinemia. The prognoses of types 1 and 2 G&#x02010;NETs are typically excellent, whereas type 3 G&#x02010;NETs are aggressive and frequently present with lymphovascular invasion and lymph node metastasis. Thus, the clinical classification affects the selected treatment strategies, such as endoscopic surveillance, endoscopic resection, or gastrectomy with lymphadenectomy. Although these clinicopathological features have been extensively studied,<xref rid="deo270088-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270088-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270088-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270088-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="deo270088-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> information on the endoscopic features of G&#x02010;NETs, particularly the magnifying narrow&#x02010;band imaging (M&#x02010;NBI) endoscopic features, is limited. We therefore investigated the endoscopic and clinicopathological findings to elucidate the endoscopic characteristics of G&#x02010;NETs.</p></sec><sec id="deo270088-sec-0060"><title>METHODS</title><sec id="deo270088-sec-0070"><title>Study design and setting</title><p>This retrospective study was conducted at a Japanese referral cancer center. The study protocol was approved by the Institutional Review Board on February 14, 2024 (22166&#x02010;2), and the study complied with the Helsinki Declaration of 1964 and later versions. The need for informed consent for study participation was waived because this was a retrospective study of anonymized data.</p></sec><sec id="deo270088-sec-0080"><title>Participants</title><p>Consecutive patients with gastric tumors, including a NET component based on the histological diagnosis of an endoscopic biopsy or resected specimens from January 2005 to December 2023, were identified in our pathology database. Among these, patients with G&#x02010;NETs were eligible for inclusion in this study. Patients with NET&#x02010;G3 were excluded because a NET&#x02010;G3 was classified as an NEC in the WHO 2010 classification<xref rid="deo270088-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>. Patients with G&#x02010;NETs not treated by endoscopic or surgical resection were also excluded because of reported inconsistencies in the tumor grade between biopsy and final resected histology findings<xref rid="deo270088-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>.</p></sec><sec id="deo270088-sec-0090"><title>Data collection</title><p>The collected data included age, sex, endoscopic findings on white&#x02010;light imaging (WLI) and M&#x02010;NBI, gastric mucosal atrophy, presence of anti&#x02010;parietal cell antibodies (APC&#x02010;Ab), <italic toggle="yes">Helicobacter pylori</italic> infection, serum gastrin concentration, treatment method, and histological findings such as tumor size, invasion depth, tumor grade, and lymphovascular invasion. Gastric mucosal atrophy was classified into C&#x02010;1, C&#x02010;2, C&#x02010;3, O&#x02010;1, O&#x02010;2, and O&#x02010;3 in accordance with Kimura&#x02010;Takemoto classification<xref rid="deo270088-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, with C&#x02010;1 defined as negative and the remainder defined as positive. <italic toggle="yes">H. pylori</italic> infection was assessed by serum antibody against <italic toggle="yes">H. pylori</italic> or histological examination. A positive result in either test indicated <italic toggle="yes">H. pylori</italic> infection. In patients with multiple G&#x02010;NETs, only the lesion with the most advanced histology or the largest lesion was studied.</p></sec><sec id="deo270088-sec-0100"><title>Assessment of endoscopic findings</title><p>Endoscopic findings were retrieved from the endoscopy report and confirmed by the investigators (Katsunori Matsueda and Noriya Uedo) after reviewing the endoscopic images stored on an endoscopic image server (Solemio ENDO version 3.3; Olympus Medical Systems). Prior to 2005, examinations were carried out with WLI using non&#x02010;magnifying endoscopes (EVIS GIF&#x02010;XQ&#x02010;240 or &#x02010;Q240; Olympus), and then magnifying endoscopes (EVIS GIF&#x02010;Q240Z, &#x02010;H260Z, &#x02010;H290Z, or &#x02010;XZ1200; Olympus) were used with NBI in most cases. The macroscopic type was assessed in accordance with the Japanese classification of gastric carcinoma<xref rid="deo270088-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>. The lesion color was classified as reddish, isochromatic, or whitish in comparison with the surrounding mucosa. On WLI, the prevalence of the known three characteristic features of G&#x02010;NETs was evaluated: (1) dilated vessels (Figure&#x000a0;<xref rid="deo270088-fig-0001" ref-type="fig">1a</xref>), (2) submucosal tumor (SMT)&#x02010;like marginal elevation (Figure&#x000a0;<xref rid="deo270088-fig-0001" ref-type="fig">1a,b</xref>), and (3) central depression (Figure 1b,c).<xref rid="deo270088-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo270088-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="deo270088-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270088-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo270088-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> SMT&#x02010;like marginal elevation was defined as a finding in which the margins of the elevation were covered by non&#x02010;neoplastic surrounding mucosa. For M&#x02010;NBI endoscopic findings, the microsurface (MS) and microvascular (MV) patterns were classified as regular, irregular, or absent<xref rid="deo270088-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>.</p><fig position="float" fig-type="FIGURE" id="deo270088-fig-0001"><label>FIGURE 1</label><caption><p>Distinctive endoscopic features of gastric neuroendocrine tumors: (a) dilated vessels (white arrows) and submucosal tumor&#x02010;like marginal elevation (yellow arrow), (b) submucosal tumor&#x02010;like marginal elevation (yellow arrows) and a central depression (light blue arrow), and (c) central depression (light blue arrow).</p></caption><graphic xlink:href="DEO2-5-e70088-g003" position="anchor" id="jats-graphic-1"/></fig><p>Two endoscopists (Katsunori Matsueda and Noriya Uedo) reviewed all recorded endoscopic images, diagnosed the endoscopic findings, and rechecked the endoscopic images if the diagnoses differed.</p></sec><sec id="deo270088-sec-0110"><title>Evaluation of histological findings</title><p>All G&#x02010;NETs were diagnosed histologically in accordance with the WHO 2019 classification<xref rid="deo270088-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>. Well&#x02010;differentiated NETs with a Ki&#x02010;67 index of &#x02264;20% were defined as NETs (G1/G2). On the basis of the WHO classification, epithelial tumors containing a mixture of NEN and non&#x02010;NEN with &#x02265;30% of each component in the tumor were classified as mixed neuroendocrine&#x02010;non&#x02010;NENs (MiNENs). G&#x02010;NET was diagnosed based on a NET (G1/G2) component of &#x02265;70%.</p><p>The degree of histological differentiation, tumor size, invasion depth, tumor grade, and lymphovascular invasion was evaluated by an expert gastrointestinal pathologist (Masanori Kitamura) who was blinded to the clinical information. All G&#x02010;NET cases were reconfirmed as having neuroendocrine differentiation by immunohistochemical staining for chromogranin A, synaptophysin, and CD56. The tumors were classified by Ki&#x02010;67 proliferation indices as G1&#x000a0;(&#x0003c;3%) or G2 (3%&#x02013;20%). The presence of ECL cell hyperplasia and endocrine cell micronests was assessed in the surrounding non&#x02010;neoplastic mucosa.</p></sec><sec id="deo270088-sec-0120"><title>Clinical classification of G&#x02010;NETs</title><p>The diagnosis of type 1 G&#x02010;NET was based on the following criteria: (i) no evidence of multiple endocrine neoplasia Zollinger&#x02010;Ellison syndrome, (ii) APC&#x02010;Ab positivity, or (iii) presence of ECL cell hyperplasia/endocrine cell micronests and fundic gland atrophy in histology; or (iv) evidence of hypergastrinemia&#x000a0;(&#x0003e;450 pg/mL) in cases with no evidence of APC&#x02010;Abs or ECL cell hyperplasia/endocrine cell micronests. Type 2 G&#x02010;NETs were defined as those with the presence of multiple endocrine neoplasia type I or Zollinger&#x02010;Ellison syndrome. Tumors that did not meet the criteria for types 1 and 2 were classified as type 3 G&#x02010;NETs.</p></sec><sec id="deo270088-sec-0130"><title>Treatment strategy</title><p>The initial treatment method of G&#x02010;NETs, endoscopic or surgical resection, was determined based on a policy following the Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms in Japan<xref rid="deo270088-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>. For type 1 G&#x02010;NETs, endoscopic resection was proposed for tumors &#x02264;1&#x000a0;cm, with no more than several tumors confined to the submucosa without lymph node metastasis. On the other hand, surgical resection was essentially indicated for type 3 G&#x02010;NETs and tumors that did not meet the criteria for endoscopic resection.</p></sec><sec id="deo270088-sec-0140"><title>Measured outcomes</title><p>The primary analysis aimed to clarify the prevalence of characteristic endoscopic findings of G&#x02010;NETs. To elucidate the histological findings behind the characteristic endoscopic findings of the G&#x02010;NET, the predominance of tumor localization in the mucosa or submucosa and the distance between the tumor and the surface epithelium were assessed. The tumor localization was determined as mucosa&#x02010;predominant or submucosa&#x02010;predominant depending on whether the tumor epicenter was above or below the muscularis mucosae in the specimen with the maximum tumor diameter. The closest distance between the tumor edge and the surface epithelium was measured using a virtual pathology system (cellSens V3.1 imaging software; Olympus Corp.).</p><p>Ancillary analyses compared the endoscopic findings of G&#x02010;NETs in accordance with the clinical classification.</p></sec><sec id="deo270088-sec-0150"><title>Statistical analyses</title><p>Continuous variables were reported as median (range) and compared using Wilcoxon rank sum test, while categorical variables were reported as frequency (percentage) and compared using Pearson's &#x003c7;<sup>2</sup> test or Fisher's exact test. <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.05 was considered statistically significant. All statistical analyses were performed using JMP 17 software (SAS Institute Inc.).</p></sec></sec><sec id="deo270088-sec-0160"><title>RESULTS</title><sec id="deo270088-sec-0170"><title>Patient and tumor characteristics</title><p>Forty&#x02010;six patients with gastric tumors with a NET component were identified during the study period. Among these, 14 patients who did not undergo resection, two with MiNENs, and one with adenocarcinoma with a NET component of&#x000a0;&#x0003c;30% were excluded, leaving 29 patients with G&#x02010;NETs for analysis (Figure&#x000a0;<xref rid="deo270088-fig-0002" ref-type="fig">2</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270088-fig-0002"><label>FIGURE 2</label><caption><p>Flowchart of patient selection: NET, neuroendocrine tumor; G&#x02010;NET, gastric neuroendocrine tumor; MiNEN, mixed neuroendocrine&#x02010;non&#x02010;neuroendocrine neoplasm.</p></caption><graphic xlink:href="DEO2-5-e70088-g002" position="anchor" id="jats-graphic-3"/></fig><p>The clinicopathological data of the 29 patients and their main lesions are shown in Table&#x000a0;<xref rid="deo270088-tbl-0001" ref-type="table">1</xref>. Eleven patients (38%) had multiple lesions. The main initial treatment methods were endoscopic treatment, endoscopic mucosal resection (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;11, 38%), and endoscopic submucosal dissection (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;11, 38%). The median histological tumor size was 5 (range: 1&#x02013;35) mm. There were 25 G1 lesions (86%) and four G2 lesions (14%).</p><table-wrap position="float" id="deo270088-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Clinicopathological characteristics of 29 patients with gastric neuroendocrine tumors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Clinicopathological findings</th><th align="left" rowspan="1" colspan="1">
<p>Total</p>
<p>(<italic toggle="yes">n</italic>&#x000a0;= 29)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age in years, median (range)</td><td align="left" rowspan="1" colspan="1">64 (33&#x02013;82)</td></tr><tr><td align="left" colspan="2" rowspan="1">Sex, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">14 (48)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">15 (52)</td></tr><tr><td align="left" colspan="2" rowspan="1">Number of tumors, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">18 (62)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multiple</td><td align="left" rowspan="1" colspan="1">11 (38)</td></tr><tr><td align="left" colspan="2" rowspan="1">Initial treatment, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">EMR</td><td align="left" rowspan="1" colspan="1">11 (38)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ESD</td><td align="left" rowspan="1" colspan="1">11 (38)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1">7 (24)</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological tumor size in mm, median (range)</td><td align="left" rowspan="1" colspan="1">5 (1&#x02013;35)</td></tr><tr><td align="left" colspan="2" rowspan="1">Histological depth, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">T1a (M)</td><td align="left" rowspan="1" colspan="1">10 (34)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">T1b (SM)</td><td align="left" rowspan="1" colspan="1">19 (66)</td></tr><tr><td align="left" colspan="2" rowspan="1">Tumor grade, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Grade 1</td><td align="left" rowspan="1" colspan="1">25 (86)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Grade 2</td><td align="left" rowspan="1" colspan="1">4 (14)</td></tr><tr><td align="left" colspan="2" rowspan="1">Lymphovascular involvement, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">4 (14)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">25 (86)</td></tr><tr><td align="left" colspan="2" rowspan="1">APC&#x02010;Ab, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">2 (7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not tested</td><td align="left" rowspan="1" colspan="1">26 (90)</td></tr><tr><td align="left" colspan="2" rowspan="1">
<italic toggle="yes">H. pylori</italic> infection</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">24 (83)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not tested</td><td align="left" rowspan="1" colspan="1">5 (17)</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum gastrin concentration in pg/mL, median (range)</td><td align="left" rowspan="1" colspan="1">721 (61&#x02013;9760)</td></tr><tr><td align="left" colspan="2" rowspan="1">Hypergastrinemia</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">10 (34)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">8 (28)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not tested</td><td align="left" rowspan="1" colspan="1">11 (38)</td></tr><tr><td align="left" colspan="2" rowspan="1">ECL cell hyperplasia or ECM in the background mucosa, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">18 (62)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">10 (34)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not tested</td><td align="left" rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" colspan="2" rowspan="1">Clinical classification by Rindi et&#x000a0;al.,&#x000a0;<italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 1</td><td align="left" rowspan="1" colspan="1">20 (69)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Type 3</td><td align="left" rowspan="1" colspan="1">9 (31)</td></tr></tbody></table><table-wrap-foot><fn id="deo270088-tbl1-note-0001"><p>Abbreviations: APC&#x02010;Ab, anti&#x02010;parietal cell antibodies; ECL, enterochromaffin&#x02010;like; ECM, endocrine cell micronest; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; M, mucosa; SM, submucosa.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270088-sec-0180"><title>Characteristic endoscopic findings</title><p>The endoscopic findings of the 29 G&#x02010;NETs are summarized in Table&#x000a0;<xref rid="deo270088-tbl-0002" ref-type="table">2</xref>. M&#x02010;NBI was evaluable in 21 cases.</p><table-wrap position="float" id="deo270088-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Endoscopic characteristics of gastric neuroendocrine tumors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1">Endoscopic findings</th><th align="left" rowspan="1" colspan="1">
<p>Total</p>
<p>(<italic toggle="yes">n</italic>&#x000a0;= 29)</p>
</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Clinical classification by Rindi et&#x000a0;al.</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Type&#x000a0;1</p>
<p>(<italic toggle="yes">n</italic>&#x000a0;= 20)</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Type 3</p>
<p>(<italic toggle="yes">n</italic>&#x000a0;= 9)</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p&#x02010;</italic>value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Gastric mucosal atrophy, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">7 (24)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">7 (78)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">22 (76)</td><td align="left" rowspan="1" colspan="1">20 (100)</td><td align="left" rowspan="1" colspan="1">2 (22)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Gastric mucosal atrophy by Kimura&#x02010;Takemoto classification, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">C&#x02010;1</td><td align="left" rowspan="1" colspan="1">7 (24)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">7 (78)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">C&#x02010;2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">C&#x02010;3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">O&#x02010;1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">O&#x02010;2</td><td align="left" rowspan="1" colspan="1">6 (21)</td><td align="left" rowspan="1" colspan="1">5 (25)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">O&#x02010;3</td><td align="left" rowspan="1" colspan="1">16 (55)</td><td align="left" rowspan="1" colspan="1">15 (75)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histological tumor size in mm, median (range)</td><td align="left" rowspan="1" colspan="1">5 (1&#x02013;35)</td><td align="left" rowspan="1" colspan="1">6 (2&#x02013;27)</td><td align="left" rowspan="1" colspan="1">5 (1&#x02013;35)</td><td align="left" rowspan="1" colspan="1">0.685</td></tr><tr><td align="left" colspan="5" rowspan="1">Location in the stomach, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Upper third</td><td align="left" rowspan="1" colspan="1">14 (48)</td><td align="left" rowspan="1" colspan="1">9 (45)</td><td align="left" rowspan="1" colspan="1">5 (56)</td><td align="left" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Middle third</td><td align="left" rowspan="1" colspan="1">15 (52)</td><td align="left" rowspan="1" colspan="1">11 (55)</td><td align="left" rowspan="1" colspan="1">4 (44)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Tumor color, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Reddish</td><td align="left" rowspan="1" colspan="1">19 (66)</td><td align="left" rowspan="1" colspan="1">18 (90)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Isochromatic</td><td align="left" rowspan="1" colspan="1">10 (34)</td><td align="left" rowspan="1" colspan="1">2 (10)</td><td align="left" rowspan="1" colspan="1">8 (89)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Macroscopic type, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Advanced cancer&#x02010;like protruding lesion</td><td align="left" rowspan="1" colspan="1">2 (7)</td><td align="left" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1">0.548</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Superficial protruded/elevated lesion</td><td align="left" rowspan="1" colspan="1">24 (83)</td><td align="left" rowspan="1" colspan="1">17 (85)</td><td align="left" rowspan="1" colspan="1">7 (78)</td><td align="left" rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Superficial depressed lesion</td><td align="left" rowspan="1" colspan="1">3 (10)</td><td align="left" rowspan="1" colspan="1">2 (10)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1">0.928</td></tr><tr><td align="left" colspan="5" rowspan="1">Dilated vessels, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">24 (83)</td><td align="left" rowspan="1" colspan="1">18 (90)</td><td align="left" rowspan="1" colspan="1">6 (67)</td><td align="left" rowspan="1" colspan="1">0.124</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">5 (17)</td><td align="left" rowspan="1" colspan="1">2 (10)</td><td align="left" rowspan="1" colspan="1">3 (33)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">SMT&#x02010;like marginal elevation, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">17 (59)</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">7 (78)</td><td align="left" rowspan="1" colspan="1">0.160</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">12 (41)</td><td align="left" rowspan="1" colspan="1">10 (50)</td><td align="left" rowspan="1" colspan="1">2 (22)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Central depression, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">14 (48)</td><td align="left" rowspan="1" colspan="1">14 (70)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">15 (52)</td><td align="left" rowspan="1" colspan="1">6 (30)</td><td align="left" rowspan="1" colspan="1">9 (100)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Macroscopic subtype, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Reddish polypoid lesion</td><td align="left" rowspan="1" colspan="1">17 (59)</td><td align="left" rowspan="1" colspan="1">16 (80)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SMT&#x02010;like lesion</td><td align="left" rowspan="1" colspan="1">9 (31)</td><td align="left" rowspan="1" colspan="1">2 (10)</td><td align="left" rowspan="1" colspan="1">7 (78)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Unclassifiable</td><td align="left" rowspan="1" colspan="1">3 (10)</td><td align="left" rowspan="1" colspan="1">2 (10)</td><td align="left" rowspan="1" colspan="1">1 (11)</td><td align="left" rowspan="1" colspan="1">0.928</td></tr><tr><td align="left" colspan="5" rowspan="1">MS pattern on M&#x02010;NBI<xref rid="deo270088-tbl2-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regular</td><td align="left" rowspan="1" colspan="1">11 (52)</td><td align="left" rowspan="1" colspan="1">3 (23)</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Irregular</td><td align="left" rowspan="1" colspan="1">1 (5)</td><td align="left" rowspan="1" colspan="1">1 (8)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.422</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">9 (43)</td><td align="left" rowspan="1" colspan="1">9 (69)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" colspan="5" rowspan="1">MV pattern on M&#x02010;NBI<xref rid="deo270088-tbl2-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Regular</td><td align="left" rowspan="1" colspan="1">10 (48)</td><td align="left" rowspan="1" colspan="1">3 (23)</td><td align="left" rowspan="1" colspan="1">7 (88)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Irregular</td><td align="left" rowspan="1" colspan="1">11 (52)</td><td align="left" rowspan="1" colspan="1">10 (77)</td><td align="left" rowspan="1" colspan="1">1 (13)</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" colspan="5" rowspan="1">Absent MS pattern plus irregular MV pattern<xref rid="deo270088-tbl2-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">9 (43)</td><td align="left" rowspan="1" colspan="1">9 (69)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">12 (57)</td><td align="left" rowspan="1" colspan="1">4 (31)</td><td align="left" rowspan="1" colspan="1">8 (100)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270088-tbl2-note-0001"><p>Abbreviations: M&#x02010;NBI, magnifying narrow&#x02010;band imaging; MS, microsurface; MV, microvascular; SMT, submucosal tumor.</p></fn><fn id="deo270088-tbl2-note-0002"><label>*</label><p>M&#x02010;NBI findings were not available for seven cases and were not evaluable because of an adherent white coat in one case.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Nineteen lesions (66%) were reddish in color. Twenty&#x02010;six lesions (90%) presented as superficial elevated (0&#x02010;IIa) or protruded (0&#x02010;I or 1) lesions. The characteristic features of G&#x02010;NETs on WLI were frequently prevalent: dilated vessels (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;24, 83%), SMT&#x02010;like marginal elevation (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;17, 59%), and a central depression (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;14, 48%).</p><p>The G&#x02010;NETs were classified into two macroscopic subtypes. (1) Reddish polypoid lesions (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;17, 59%; Figures&#x000a0;<xref rid="deo270088-fig-0001" ref-type="fig">1b,c</xref>, <xref rid="deo270088-fig-0003" ref-type="fig">3a</xref>, and&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4a</xref>) with an enlarged groove&#x02010;type mucosal structure. A central depression was seen in 14 lesions (14/17, 82%). All lesions in which MS and MV patterns were evaluable in the central depression under M&#x02010;NBI had an absent MS pattern plus an irregular MV pattern (9/9, 100%, Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3b,c</xref>). (2) SMT&#x02010;like lesions (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;9, 31%; Figures&#x000a0;<xref rid="deo270088-fig-0001" ref-type="fig">1a</xref> and&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4d</xref>). Eight of these were isochromatic (89%). All lesions in which MS and MV patterns were evaluable showed a regular MS plus a regular MV pattern without a demarcation line (100%, 7/7; Figure&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4e</xref>). The other three cases (10%) were unclassifiable.</p><fig position="float" fig-type="FIGURE" id="deo270088-fig-0003"><label>FIGURE 3</label><caption><p>Representative case of the reddish polypoid lesion: (a) white&#x02010;light imaging shows a reddish superficial elevated lesion with a central depression on the posterior wall in the middle third of the stomach, (b) magnifying narrow&#x02010;band imaging reveals an absent microsurface pattern plus an irregular microvascular pattern in the depressed area, which is surrounded by an enlarged groove&#x02010;type mucosal structure (yellow box in Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3a</xref>), (c) enlarged magnifying narrow&#x02010;band imaging of the depressed area in the blue box in Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3b</xref>. The brownish irregular microvessels consist of closed (connected) looped vessels, (d) Histological examination of the endoscopic submucosal dissection specimen with hematoxylin and eosin staining along the cut surface of the white line in Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3a</xref>. The neuroendocrine tumor (NET) is composed of small uniform cells in nests predominantly located in the mucosa just below the thinned surface epithelium (magnification &#x000d7;20), (e) immunohistochemical examination for cytokeratin AE1/AE3 confirms that the non&#x02010;neoplastic surface epithelium remains thin above the NET. The presence of intramucosal NET component causes non&#x02010;neoplastic gland ducts to become sparse and shallow, resulting in the extended intervening parts between the gastric pits (indicated by blue arrows) compared with the surrounding mucosa (magnification &#x000d7;20), and (f) immunohistochemical examination for CD31 in the area in the red box in Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3d</xref> reveals dense dilated subepithelial capillaries (red arrows) in close contact on the tumor surface (light blue dashed line), flattening the surface epithelium and thinning the superficial layer of the lamina propria (magnification &#x000d7;100). These findings indicate that the NET component quite close to the surface epithelium histologically corresponds to an absent microsurface&#x000a0;pattern plus an irregular microvascular pattern on magnifying narrow&#x02010;band imaging.</p></caption><graphic xlink:href="DEO2-5-e70088-g001" position="anchor" id="jats-graphic-5"/></fig><fig position="float" fig-type="FIGURE" id="deo270088-fig-0004"><label>FIGURE 4</label><caption><p>Representative cases of type 1 and type 3 gastric neuroendocrine tumors (G&#x02010;NETs) Type 1 G&#x02010;NET: (a) white&#x02010;light imaging shows a reddish superficial protruded lesion (i.e., reddish polypoid lesion) on the greater curvature in the upper third of the stomach, (b) magnifying narrow&#x02010;band imaging shows a regular microsurface pattern plus a regular microvascular pattern on an enlarged groove&#x02010;type mucosa, (c) histological examination of the surgical specimen with hematoxylin and eosin staining reveals that the intramucosal neuroendocrine tumor (NET) close to the epithelial surface makes the gastric gland ducts sparse and shallow, resulting in the extended intervening parts between the gastric pits (blue arrows). The tumor border and muscularis mucosa are indicated by red and yellow dashed lines, respectively (magnification &#x000d7;20) Type 3 G&#x02010;NET, (d) White&#x02010;light imaging shows isochromatic submucosal tumor&#x02010;like lesions on the lesser curvature in the upper third of the stomach, (e) magnifying narrow&#x02010;band imaging reveals a regular microsurface pattern plus a regular microvascular without a demarcation line, and (f) histological examination of the surgical specimen with hematoxylin and eosin staining reveals that the NET is predominantly located in the submucosa beneath the non&#x02010;atrophic mucosa, where the normal gland ducts remain intact (magnification &#x000d7;20).</p></caption><graphic xlink:href="DEO2-5-e70088-g004" position="anchor" id="jats-graphic-7"/></fig><p>In 27 cases, histological slides were available for detailed reassessment of histological findings (Table&#x000a0;<xref rid="deo270088-tbl-0003" ref-type="table">3</xref>). Fifteen G&#x02010;NETs (56%) were predominantly located in the mucosa. The reddish polypoid lesions had a significantly shorter distance between the tumor and the surface epithelium than other lesions (<italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.001), irrespective of the predominance of tumor localization in the mucosa or submucosa (<italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.381, Figures&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3</xref> and&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4</xref>). The finding of an absent MS pattern plus an irregular MV pattern on M&#x02010;NBI was also associated with a significantly shorter distance between the tumor and the surface epithelium than in lesions without this finding (<italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.006), irrespective of the predominance of tumor localization (<italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.801, Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3</xref>).</p><table-wrap position="float" id="deo270088-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Histological findings associated with characteristic endoscopic findings.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="6" style="border-bottom:solid 1px #000000" rowspan="1">
<bold>Endoscopic findings of G&#x02010;NET</bold>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">
<bold>Histological findings</bold>
</th><th align="left" rowspan="1" colspan="1">
<p>
<bold>Total</bold>
</p>
<p>
<bold>(<italic toggle="yes">n</italic>&#x000a0;= 27)</bold>
<xref rid="deo270088-tbl3-note-0002" ref-type="table-fn">
<sup>*</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>
<bold>Reddish polypoid lesion</bold>
</p>
<p>
<bold>(<italic toggle="yes">n</italic>&#x000a0;= 16)</bold>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>
<bold>Others</bold>
</p>
<p>
<bold>(<italic toggle="yes">n</italic>&#x000a0;= 11)</bold>
</p>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p&#x02010;</italic>value</bold>
</th><th align="left" rowspan="1" colspan="1">
<p>
<bold>Absent MS+irregular MV present</bold>
</p>
<p>
<bold>(<italic toggle="yes">n</italic>&#x000a0;= 9)</bold>
<xref rid="deo270088-tbl3-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>
<bold>Absent MS+irregular MV absent</bold>
</p>
<p>
<bold>(<italic toggle="yes">n</italic>&#x000a0;= 12)</bold>
<xref rid="deo270088-tbl3-note-0003" ref-type="table-fn">
<sup>**</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p&#x02010;</italic>value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Tumor localization, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.381</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.801</td></tr><tr><td align="left" rowspan="1" colspan="1">Mucosa predominant</td><td align="left" rowspan="1" colspan="1">15 (56)</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Submucosa predominant</td><td align="left" rowspan="1" colspan="1">12 (44)</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Distance from the epithelium in &#x000b5;m, median (range)</td><td align="left" rowspan="1" colspan="1">
<p>76</p>
<p>(0&#x02013;2239)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>36</p>
<p>(0&#x02013;288)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>387</p>
<p>(0&#x02013;2239)</p>
</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">
<p>36</p>
<p>(0&#x02013;288)</p>
</td><td align="left" rowspan="1" colspan="1">
<p>290</p>
<p>(26&#x02013;2239)</p>
</td><td align="left" rowspan="1" colspan="1">0.006</td></tr></tbody></table><table-wrap-foot><fn id="deo270088-tbl3-note-0001"><p>Abbreviations: G&#x02010;NET, gastric neuroendocrine tumor; MS, microsurface; MV, microvascular.</p></fn><fn id="deo270088-tbl3-note-0002"><label>*</label><p>The histological slides were not evaluated for two cases because the specimens had been discarded.</p></fn><fn id="deo270088-tbl3-note-0003"><label>**</label><p>Magnifying narrow&#x02010;band imaging findings were available for 21 cases.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270088-sec-0190"><title>Endoscopic findings in accordance with the clinical classification</title><p>There were no type 2 G&#x02010;NETs. APC&#x02010;Ab testing was performed in three cases, among which one was positive. Therefore, the clinical subtypes were classified mainly based on the histological findings of the surrounding mucosa or evidence of hypergastrinemia (Table&#x000a0;<xref rid="deo270088-tbl-0001" ref-type="table">1</xref>). Accordingly, 20 lesions (69%) were diagnosed as type 1 G&#x02010;NETs and nine (31%) were classified as type 3 G&#x02010;NETs.</p><p>Table&#x000a0;<xref rid="deo270088-tbl-0002" ref-type="table">2</xref> lists the endoscopic findings of G&#x02010;NETs grouped by clinical classification. Gastric mucosal atrophy was more frequently observed in type 1 than in type 3 G&#x02010;NETs (100%&#x000a0;vs. 22%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). Regarding the endoscopic features on WLI, type 1 G&#x02010;NETs were more frequently a reddish color, while type 3 G&#x02010;NETs were more frequently isochromatic (<italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001, Figure&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4</xref>). A central depression was more frequent in type 1 G&#x02010;NETs than in type 3 G&#x02010;NETs (70%&#x000a0;vs. 0%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). Regarding the macroscopic subtypes, reddish polypoid lesions were significantly more frequent in type 1 G&#x02010;NETs than in type 3 G&#x02010;NETs (80%&#x000a0;vs. 11%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001), whereas SMT&#x02010;like lesions were significantly more frequent in type 3 G&#x02010;NETs than in type 1 G&#x02010;NETs (78%&#x000a0;vs. 10%, <italic toggle="yes">p&#x000a0;</italic>&#x0003c;&#x000a0;0.001). On M&#x02010;NBI endoscopy findings, an absent MS pattern plus an irregular MV pattern was significantly more frequent in type 1 G&#x02010;NETs than in type 3 G&#x02010;NETs (69%&#x000a0;vs. 0%, <italic toggle="yes">p&#x000a0;</italic>=&#x000a0;0.002).</p></sec></sec><sec id="deo270088-sec-0200"><title>DISCUSSION</title><p>To the best of our knowledge, this is the first study to elucidate the characteristic endoscopic findings of G&#x02010;NETs in relation to histological findings.</p><p>G&#x02010;NETs originate from endocrine progenitor cells in the basal layer of the mucosa and then gradually proliferate and expand into the mucosa and submucosa, lifting up the surrounding non&#x02010;neoplastic mucosa.<xref rid="deo270088-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270088-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> This growth pattern explains the appearance of SMT&#x02010;like marginal elevation. Dilated vessels appeared to result from congestion caused by pressure from the subepithelial tumor and elevation of the vessels to the superficial layer of the mucosa. Although NETs have characteristics of SMTs, neoplastic endocrine cells proliferate within both the lamina propria and the submucosa. In our study, more than half (56%) of the lesions were predominantly located in the mucosa, thereby forming a tumor frequently accompanied by epithelial changes such as a reddish color or central depression.<xref rid="deo270088-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo270088-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The most characteristic WLI endoscopic findings of G&#x02010;NETs were a combination of SMT&#x02010;like marginal elevation, a reddish color, and a central depression, which are features that indicate subepithelial tumor growth.</p><p>The G&#x02010;NETs had two major macroscopic subtypes, of which the most common was a reddish polypoid lesion. The reddish polypoid lesions were characterized by an enlarged groove&#x02010;type mucosal structure with/without a central depression. The extended intervening part between the gastric pits in the enlarged groove&#x02010;type mucosal structure was attributed to the histological finding that gastric pits above the NET became sparse and shallow owing to the presence of the subepithelial tumor near the surface epithelium (Figures&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3e</xref> and&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4c</xref>). We hypothesized that the reddish polypoid appearance might be formed by intramucosal tumor proliferation toward the epithelial surface. Accordingly, although the predominant proliferation of the tumor in the mucosa was not associated with the reddish polypoid appearance, we confirmed that a shorter distance between the tumor and the surface epithelium was significantly associated with the reddish polypoid appearance of the G&#x02010;NETs.</p><p>Significantly more epithelial changes such as a reddish color, central depression, or enlarged groove&#x02010;type mucosal structure were observed in type 1 G&#x02010;NETs. In contrast, type 3 G&#x02010;NETs were a non&#x02010;reddish color without epithelial changes (i.e., SMT&#x02010;like lesions). The differences in endoscopic findings between types 1 and 3 G&#x02010;NETs may be explained by the thickness of the background gastric mucosa. Both type 1 and type 3 G&#x02010;NETs originate from the basal layer of the fundic glands; however, due to mucosal atrophy in the background gastric mucosa, type 1 G&#x02010;NETs are located closer to the surface epithelium than type 3 G&#x02010;NETs. Therefore, type 1 G&#x02010;NETs are more likely to affect the epithelium, leading to a reddish polypoid appearance that is significantly associated with the shorter distance between the tumor and the surface epithelium. In addition, as gastric glands are sparsely distributed in the atrophic background mucosa of type 1 G&#x02010;NETs, the tumor cells easily extend upwards through the non&#x02010;neoplastic gastric glands (Figure 4a&#x02013;c)<xref rid="deo270088-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>. However, as the gastric mucosa is thick and the non&#x02010;atrophic gland ducts remain dense in type 3 G&#x02010;NETs, most of the surface epithelium is unaffected by the tumor, resulting in SMT&#x02010;like lesions (Figure&#x000a0;<xref rid="deo270088-fig-0004" ref-type="fig">4d&#x02013;f</xref>). In endoscopic screening/surveillance for G&#x02010;NETs in patients with autoimmune gastritis, it is important to pay attention to identifying reddish polypoid lesions rather than yellowish SMT&#x02010;like lesions like rectal NETs<xref rid="deo270088-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>.</p><p>The unique M&#x02010;NBI endoscopic finding in type 1 G&#x02010;NETs was an absent MS pattern plus an irregular MV pattern in the depressed area of reddish polypoid lesions. The MS pattern on M&#x02010;NBI is visible when epithelium with glandular structure is exposed to the surface. In G&#x02010;NETs, endocrine cells form solid nests or trabeculae structures instead of glandular structures.<xref rid="deo270088-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270088-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Moreover, although non&#x02010;neoplastic surface epithelium was preserved in most cases, the surface epithelium above type 1 G&#x02010;NETs was flat&#x02010;thinned with few non&#x02010;neoplastic gland ducts. Thus, we consider that the absent MS pattern in type 1 G&#x02010;NETs is attributed to the histological characteristic of G&#x02010;NETs and the flattened structure of the non&#x02010;neoplastic surface epithelium. Regarding the irregular MV patterns seen in type 1 G&#x02010;NETs in our study, there was debate among the investigators as to whether these vessels were neoplastic or non&#x02010;neoplastic. Some studies have described the dilated brownish microvessels in the central depression of G&#x02010;NETs as corkscrew&#x02010;shaped.<xref rid="deo270088-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270088-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270088-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> However, our detailed inspection of the MV pattern found that most irregular microvessels in the central depression of the G&#x02010;NETs were shaped as a connected loop (Figure&#x000a0;<xref rid="deo270088-fig-0003" ref-type="fig">3b,c</xref>). The connected loop vessels or fine network patterns are M&#x02010;NBI endoscopic findings of a differentiated&#x02010;type adenocarcinoma forming glandular structures.<xref rid="deo270088-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="deo270088-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> If these irregular microvessels in the depressed area are tumor vessels, they should be non&#x02010;connected loop vessels (corkscrew pattern) like in undifferentiated&#x02010;type adenocarcinomas because the NET does not form glandular structures. Furthermore, we found that the absent MS pattern plus irregular MV pattern was seen even when the tumor was up to 288&#x000a0;&#x000b5;m away from the surface epithelium. Accordingly, we speculate that the irregular MV pattern in the central depression of type 1 G&#x02010;NETs reflects a dense dilated non&#x02010;neoplastic subepithelial capillary network near the tumor surface as a result of congestion caused by an expansively growing subepithelial tumor. We believe that this M&#x02010;NBI endoscopic finding is useful to increase the index of suspicion for type 1 G&#x02010;NET and perform targeted forceps biopsy to make an accurate diagnosis.</p><p>The present study has some limitations. First, it was a retrospective, single&#x02010;center study with a small sample size. In particular, because type 2 G&#x02010;NETs were not included in the study, the endoscopic features found in this study may not be applicable to all types of G&#x02010;NETs. The limited number of patients was due to the rarity of the disease; however, the study was conducted in a specialized cancer center where all endoscopic images and histological slides were well stored. Furthermore, we carefully reviewed all the stored endoscopic and histological information to identify any associations. Our results warrant future validation in large&#x02010;scale studies of the endoscopic diagnosis of G&#x02010;NETs. Second, patients with G&#x02010;NETs who did not undergo endoscopic or surgical resection were excluded, leading to selection bias. However, we considered it important to only include patients who had undergone complete histological evaluation of the entire resected specimen to ensure an accurate diagnosis of G&#x02010;NETs (G1/G2). Third, the sensitivity of characteristic endoscopic findings for G&#x02010;NETs was assessed, but the specificity could not be determined because not all cases of non&#x02010;G&#x02010;NETs were included. However, the classification of the two macroscopic subtypes of G&#x02010;NETs defined in this study is important for clinicians to detect G&#x02010;NETs based on the presence or absence of atrophic gastritis in the background mucosa and determine a treatment strategy for G&#x02010;NETs based on the clinical classification.</p><p>In conclusion, the characteristic findings of G&#x02010;NETs on WLI were a reddish color, dilated vessels, SMT&#x02010;like marginal elevation, and a central depression. The characteristic endoscopic findings of type 1 G&#x02010;NETs were a reddish polypoid lesion with a central depression in which there was an absent MS pattern plus an irregular MV pattern on M&#x02010;NBI. Knowledge of these endoscopic features will improve the diagnostic yield of G&#x02010;NETs.</p></sec><sec sec-type="COI-statement" id="deo270088-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>Noriya Uedo received honoraria for his lectures from Olympus, Fujifilm, Boston Scientific (Japan), Daiichi Sankyo, Takeda Pharmaceutical, EA Pharma, Otsuka Pharmaceutical, AstraZeneca, Miyarisan Pharmaceutical, AI Medical Service, MC Medical, and Ryobi Systems. These organizations had no role in the design, practice, or analysis of this manuscript. The other authors declare no conflict of interest.</p></sec><sec id="deo270088-sec-0230"><title>ETHICS STATEMENT</title><p>
<bold>Approval of the research protocol by an Institutional Reviewer Board</bold>: The study protocol was approved by the Institutional Review Board on February 14, 2024 (22166&#x02010;2).</p></sec></body><back><ack id="deo270088-sec-0210"><title>ACKNOWLEDGMENTS</title><p>We thank Kelly Zammit, BVSc, from Edanz (<ext-link xlink:href="https://jp.edanz.com/ac" ext-link-type="uri">https://jp.edanz.com/ac</ext-link>) for editing a draft of this manuscript.</p></ack><ref-list id="deo270088-bibl-0001"><title>REFERENCES</title><ref id="deo270088-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270088-cite-0001">
<string-name>
<surname>Nagtegaal</surname>
<given-names>ID</given-names>
</string-name>, <string-name>
<surname>Odze</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Klimstra</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The 2019 WHO classification of tumours of the digestive system</article-title>. <source>Histopathology</source>
<year>2020</year>; <volume>76</volume>: <fpage>182</fpage>&#x02013;<lpage>188</lpage>.<pub-id pub-id-type="pmid">31433515</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270088-cite-0002">
<string-name>
<surname>Rindi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Luinetti</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Cornaggia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Capella</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Solcia</surname>
<given-names>E</given-names>
</string-name>. <article-title>Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study</article-title>. <source>Gastroenterology</source>
<year>1993</year>; <volume>104</volume>: <fpage>994</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">7681798</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270088-cite-0003">
<string-name>
<surname>Panzuto</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ramage</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pritchard</surname>
<given-names>DM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1&#x02010;G3</article-title>. <source>J Neuroendocrinol</source>
<year>2023</year>; <volume>35</volume>: <elocation-id>e13306</elocation-id>.<pub-id pub-id-type="pmid">37401795</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270088-cite-0004">
<string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Clinical features and management of type I gastric carcinoids</article-title>. <source>Clin J Gastroenterol</source>
<year>2014</year>; <volume>7</volume>: <fpage>381</fpage>&#x02013;<lpage>386</lpage>.<pub-id pub-id-type="pmid">26184015</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270088-cite-0005">
<string-name>
<surname>Hirasawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sano</surname>
<given-names>T</given-names>
</string-name>. <article-title>Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>408</fpage>&#x02013;<lpage>417</lpage>.<pub-id pub-id-type="pmid">32578248</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270088-cite-0006">
<string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Imamura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kaizaki</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Management and clinical outcomes of type I gastric carcinoid patients: Retrospective, multicenter study in Japan</article-title>. <source>Dig Endosc</source>
<year>2014</year>; <volume>26</volume>: <fpage>377</fpage>&#x02013;<lpage>384</lpage>.<pub-id pub-id-type="pmid">24188531</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270088-cite-0007">
<string-name>
<surname>Rindi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bordi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rappel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>La Rosa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stolte</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Solcia</surname>
<given-names>E</given-names>
</string-name>. <article-title>Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology, and behavior</article-title>. <source>World J Surg</source>
<year>1996</year>; <volume>20</volume>: <fpage>168</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">8661813</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0008"><label>8</label><mixed-citation publication-type="book" id="deo270088-cite-0008">
<string-name>
<surname>Rindi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Klimstra</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <part-title>Nomenclature and classification of neuroendocrine neoplasms of the digestive system</part-title>. In: WHO Classification of Tumours Editorial Board (ed). <source>WHO Classification of Tumours: Digestive System Tumours</source>, <edition>4th edn,</edition>
<publisher-loc>Lyon</publisher-loc>: <publisher-name>WHO Press</publisher-name>, <year>2010</year>; <fpage>13</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="deo270088-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270088-cite-0009">
<string-name>
<surname>Fukunaga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Machida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric type I carcinoid treated by endoscopic submucosal dissection report of a case</article-title>. <source>Stomach Intestine</source>
<year>2014</year>; <volume>49</volume>: <fpage>1223</fpage>&#x02013;<lpage>1231</lpage>.</mixed-citation></ref><ref id="deo270088-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270088-cite-0010">
<string-name>
<surname>Kimura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takemoto</surname>
<given-names>T</given-names>
</string-name>. <article-title>An endoscopic recognition of the atrophic border and its significance in chronic gastritis</article-title>. <source>Endoscopy</source>
<year>1969</year>; <volume>1</volume>: <fpage>87</fpage>&#x02013;<lpage>97</lpage>.</mixed-citation></ref><ref id="deo270088-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270088-cite-0011">
<article-title>Japanese classification of gastric carcinoma: 3rd English edition</article-title>. <source>Gastric Cancer</source>
<year>2011</year>; <volume>14</volume>: <fpage>101</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">21573743</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270088-cite-0012">
<string-name>
<surname>Nakamura</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Iida</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujishima</surname>
<given-names>M</given-names>
</string-name>. <article-title>Endoscopic features of gastric carcinoids</article-title>. <source>Gastrointest Endosc</source>
<year>1991</year>; <volume>37</volume>: <fpage>535</fpage>&#x02013;<lpage>538</lpage>.<pub-id pub-id-type="pmid">1936831</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270088-cite-0013">
<string-name>
<surname>Ichikawa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Koizumi</surname>
<given-names>W</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic mucosal resection in the management of gastric carcinoid tumors</article-title>. <source>Endoscopy</source>
<year>2003</year>; <volume>35</volume>: <fpage>203</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">12584637</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270088-cite-0014">
<string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Endoscopic diagnosis and management of type I neuroendocrine tumors</article-title>. <source>World J Gastrointest Endosc</source>
<year>2015</year>; <volume>7</volume>: <fpage>346</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="pmid">25901213</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270088-cite-0015">
<string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Terai</surname>
<given-names>S</given-names>
</string-name>. <article-title>Management of gastric and duodenal neuroendocrine tumors</article-title>. <source>World J Gastroenterol</source>
<year>2016</year>; <volume>22</volume>: <fpage>6817</fpage>&#x02013;<lpage>6828</lpage>.<pub-id pub-id-type="pmid">27570419</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270088-cite-0016">
<string-name>
<surname>Chung</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>YY</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Taiwan (DEST)</article-title>. <source>Medicine</source>
<year>2018</year>; <volume>97</volume>: <elocation-id>e12101</elocation-id>.<pub-id pub-id-type="pmid">30235663</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270088-cite-0017">
<string-name>
<surname>Yao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Anagnostopoulos</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Ragunath</surname>
<given-names>K</given-names>
</string-name>. <article-title>Magnifying endoscopy for diagnosing and delineating early gastric cancer</article-title>. <source>Endoscopy</source>
<year>2009</year>; <volume>41</volume>: <fpage>462</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">19418401</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270088-cite-0018">
<string-name>
<surname>Sanguedolce</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zanelli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Palicelli</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO,.5th edition: Similarities, differences, challenges, and unmet needs</article-title>. <source>Panminerva Med</source>
<year>2022</year>; <volume>64</volume>: <fpage>259</fpage>&#x02013;<lpage>264</lpage>.<pub-id pub-id-type="pmid">35146989</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0019"><label>19</label><mixed-citation publication-type="book" id="deo270088-cite-0019">
<collab collab-type="authors">Japanese Neuroendocrine Tumor Society</collab>
. <source>Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP&#x02010;NEN)</source>, <edition>2nd edn,</edition>
<publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanehara</publisher-name>, <year>2019</year>.</mixed-citation></ref><ref id="deo270088-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270088-cite-0020">
<string-name>
<surname>Caletti</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Guizzardi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brocchi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Grigioni</surname>
<given-names>WF</given-names>
</string-name>, <string-name>
<surname>D'Errico</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Labo</surname>
<given-names>G</given-names>
</string-name>. <article-title>Gastric carcinoid: A clinical and endoscopic assessment of four cases</article-title>. <source>Endoscopy</source>
<year>1986</year>; <volume>18</volume>: <fpage>101</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">3720680</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270088-cite-0021">
<string-name>
<surname>Hirai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ueyama</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A case of neuroendocrine tumor G1 with unique histopathological growth progress</article-title>. <source>World J Gastrointest Endosc</source>
<year>2013</year>; <volume>5</volume>: <fpage>605</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">24368937</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270088-cite-0022">
<string-name>
<surname>Wang</surname>
<given-names>XY</given-names>
</string-name>, <string-name>
<surname>Chai</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Linghu</surname>
<given-names>EQ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection</article-title>. <source>BMC Gastroenterol</source>
<year>2020</year>; <volume>20</volume>: <fpage>200</fpage>.<pub-id pub-id-type="pmid">32586282</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270088-cite-0023">
<string-name>
<surname>Kanesaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sekikawa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tsumura</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Absent microsurface pattern is characteristic of early gastric cancer of undifferentiated type: Magnifying endoscopy with narrow&#x02010;band imaging</article-title>. <source>Gastrointest Endosc</source>
<year>2014</year>; <volume>80</volume>: <fpage>1194</fpage>&#x02013;<lpage>1198</lpage>.e1.<pub-id pub-id-type="pmid">25442093</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270088-cite-0024">
<string-name>
<surname>Matsueda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kitamura</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic features of gastric neuroendocrine carcinoma</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2023</year>; <volume>38</volume>: <fpage>1808</fpage>&#x02013;<lpage>1817</lpage>.<pub-id pub-id-type="pmid">37527834</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270088-cite-0025">
<string-name>
<surname>Chon&#x000e9;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rivory</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric neuroendocrine tumors display deep invasive features, with amorphous pit and irregular vascular pattern, using narrow&#x02010;band imaging and magnification</article-title>. <source>Endoscopy</source>
<year>2018</year>; <volume>50</volume>: <fpage>E199</fpage>&#x02013;<lpage>e201</lpage>.<pub-id pub-id-type="pmid">29879738</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo270088-cite-0026">
<string-name>
<surname>Kanesaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uedo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Doyama</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Diagnosis of histological type of early gastric cancer by magnifying narrow&#x02010;band imaging: A multicenter prospective study</article-title>. <source>DEN Open</source>
<year>2022</year>; <volume>2</volume>: <elocation-id>e61</elocation-id>.<pub-id pub-id-type="pmid">35310740</pub-id>
</mixed-citation></ref><ref id="deo270088-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270088-cite-0027">
<string-name>
<surname>Nakayoshi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tajiri</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kaise</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ikegami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>H</given-names>
</string-name>. <article-title>Magnifying endoscopy combined with narrow band imaging system for early gastric cancer: Correlation of vascular pattern with histopathology (including video)</article-title>. <source>Endoscopy</source>
<year>2004</year>; <volume>36</volume>: <fpage>1080</fpage>&#x02013;<lpage>1084</lpage>.<pub-id pub-id-type="pmid">15578298</pub-id>
</mixed-citation></ref></ref-list></back></article>